Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 3/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925387 | 0.90 | DRD4 (0.46) | HTR2ADRD3HTR1ADRD4SLC6A4 | |
| SCHEMBL6923619 | 0.89 | DRD3 (0.47) | HTR2ADRD3HTR1ADRD4SLC6A4 | |
| SCHEMBL6925946 | 0.87 | TDO2 (0.45) | HTR2ADRD3HTR1ADRD4SLC6A4 | |
| SCHEMBL7670455 | 0.86 | LRRK2 (0.44) | HTR2ADRD3HTR1ADRD4TDO2 | |
| SCHEMBL6927588 | 0.86 | DRD3 (0.47) | HTR2ADRD3HTR1ADRD4SLC6A4 | |
| SCHEMBL6920200 | 0.86 | CHRNA7 (0.45) | DRD3TDO2TLR9TLR8TLR7 | |
| SCHEMBL6927304 | 0.85 | DRD4 (0.59) | HTR2ADRD3HTR1ADRD4SLC6A4 | |
| SCHEMBL6926756 | 0.85 | TDO2 (0.58) | HTR2ADRD3HTR1ADRD4SLC6A4 | |
| SCHEMBL6928182 | 0.85 | CNR2 (0.46) | TDO2TLR9TLR8TLR7GAA | |
| SCHEMBL6927079 | 0.84 | TDO2 (0.43) | HTR2ADRD3HTR1ADRD4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | HTR2A 169/4885DRD3 1478/4885HTR1A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.